Logo image of BBNX

BETA BIONICS INC (BBNX) Stock Fundamental Analysis

NASDAQ:BBNX - US08659B1026 - Common Stock

18.84 USD
+0.13 (+0.69%)
Last: 8/29/2025, 8:07:46 PM
18.84 USD
0 (0%)
After Hours: 8/29/2025, 8:07:46 PM
Fundamental Rating

3

Taking everything into account, BBNX scores 3 out of 10 in our fundamental rating. BBNX was compared to 185 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for BBNX as it has an excellent financial health rating, but there are worries on the profitability. BBNX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year BBNX has reported negative net income.
In the past year BBNX has reported a negative cash flow from operations.
BBNX Yearly Net Income VS EBIT VS OCF VS FCFBBNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M

1.2 Ratios

BBNX's Return On Assets of -36.59% is on the low side compared to the rest of the industry. BBNX is outperformed by 61.62% of its industry peers.
With a Return On Equity value of -72.04%, BBNX perfoms like the industry average, outperforming 40.54% of the companies in the same industry.
Industry RankSector Rank
ROA -36.59%
ROE -72.04%
ROIC N/A
ROA(3y)-86.31%
ROA(5y)N/A
ROE(3y)-215.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BBNX Yearly ROA, ROE, ROICBBNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

BBNX has a Gross Margin of 55.11%. This is comparable to the rest of the industry: BBNX outperforms 50.27% of its industry peers.
The Profit Margin and Operating Margin are not available for BBNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 55.11%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BBNX Yearly Profit, Operating, Gross MarginsBBNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 -10K -20K -30K

8

2. Health

2.1 Basic Checks

BBNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
BBNX has about the same amout of shares outstanding than it did 1 year ago.
BBNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BBNX Yearly Shares OutstandingBBNX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M
BBNX Yearly Total Debt VS Total AssetsBBNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 50M 100M

2.2 Solvency

An Altman-Z score of 4.18 indicates that BBNX is not in any danger for bankruptcy at the moment.
The Altman-Z score of BBNX (4.18) is better than 75.14% of its industry peers.
BBNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.18
ROIC/WACCN/A
WACC8.86%
BBNX Yearly LT Debt VS Equity VS FCFBBNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

BBNX has a Current Ratio of 6.29. This indicates that BBNX is financially healthy and has no problem in meeting its short term obligations.
BBNX has a Current ratio of 6.29. This is amongst the best in the industry. BBNX outperforms 82.70% of its industry peers.
A Quick Ratio of 5.66 indicates that BBNX has no problem at all paying its short term obligations.
BBNX's Quick ratio of 5.66 is amongst the best of the industry. BBNX outperforms 84.32% of its industry peers.
Industry RankSector Rank
Current Ratio 6.29
Quick Ratio 5.66
BBNX Yearly Current Assets VS Current LiabilitesBBNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 20M 40M 60M 80M 100M

4

3. Growth

3.1 Past

The earnings per share for BBNX have decreased strongly by -24.17% in the last year.
Looking at the last year, BBNX shows a very strong growth in Revenue. The Revenue has grown by 442.93%.
EPS 1Y (TTM)-24.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.93%
Revenue 1Y (TTM)442.93%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%144.79%

3.2 Future

Based on estimates for the next years, BBNX will show a small growth in Earnings Per Share. The EPS will grow by 2.90% on average per year.
Based on estimates for the next years, BBNX will show a very strong growth in Revenue. The Revenue will grow by 37.12% on average per year.
EPS Next Y-1.65%
EPS Next 2Y4.57%
EPS Next 3Y2.9%
EPS Next 5YN/A
Revenue Next Year40.53%
Revenue Next 2Y37.52%
Revenue Next 3Y37.12%
Revenue Next 5YN/A

3.3 Evolution

BBNX Yearly Revenue VS EstimatesBBNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 50M 100M 150M
BBNX Yearly EPS VS EstimatesBBNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -0.5 -1 -1.5 -2

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BBNX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BBNX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BBNX Price Earnings VS Forward Price EarningsBBNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BBNX Per share dataBBNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.57%
EPS Next 3Y2.9%

0

5. Dividend

5.1 Amount

No dividends for BBNX!.
Industry RankSector Rank
Dividend Yield N/A

BETA BIONICS INC

NASDAQ:BBNX (8/29/2025, 8:07:46 PM)

After market: 18.84 0 (0%)

18.84

+0.13 (+0.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-29 2025-07-29/amc
Earnings (Next)N/A N/A
Inst Owners93.13%
Inst Owner Change5.18%
Ins Owners6.49%
Ins Owner Change7.43%
Market Cap818.97M
Analysts84
Price Target24.14 (28.13%)
Short Float %10.93%
Short Ratio7.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.47%
PT rev (3m)-7.96%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)2.93%
EPS NY rev (3m)9.76%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)7.6%
Revenue NY rev (3m)7.73%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.58
P/FCF N/A
P/OCF N/A
P/B 10.77
P/tB 10.77
EV/EBITDA N/A
EPS(TTM)-1.28
EYN/A
EPS(NY)-2.16
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.11
OCFYN/A
SpS1.5
BVpS1.75
TBVpS1.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.59%
ROE -72.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 55.11%
FCFM N/A
ROA(3y)-86.31%
ROA(5y)N/A
ROE(3y)-215.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 148.71%
Cap/Sales 5.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.29
Quick Ratio 5.66
Altman-Z 4.18
F-Score5
WACC8.86%
ROIC/WACCN/A
Cap/Depr(3y)68.31%
Cap/Depr(5y)N/A
Cap/Sales(3y)146.62%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-24.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.93%
EPS Next Y-1.65%
EPS Next 2Y4.57%
EPS Next 3Y2.9%
EPS Next 5YN/A
Revenue 1Y (TTM)442.93%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%144.79%
Revenue Next Year40.53%
Revenue Next 2Y37.52%
Revenue Next 3Y37.12%
Revenue Next 5YN/A
EBIT growth 1Y-26.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-42.59%
EBIT Next 3Y-13.58%
EBIT Next 5YN/A
FCF growth 1Y-57.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.78%
OCF growth 3YN/A
OCF growth 5YN/A